Table 3.
Trends in age-standardized five-year net survival of screened and non-screened breast cancers diagnosed during 1995–2011 among women in England
| Segment | Screened | Segment | Non-screened | pparallelism for screened vs non-screened | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Start year, NS, % | End year, NS, % | APC (95% CI) | p parallelism | Start year, NS, % | End year, NS, % | APC (95% CI) | p parallelism | ||||
| All | 1995–2011 | 96 | 100 | 0.1 (0.4 to 1.0) | 1995–2008 | 77 | 81 | 0.3 (0.1 to 0.6) | <0.001 | ||
| 2008–2011 | 81 | 95 | 5.7 (4.3 to 7.1) | ||||||||
| Race | |||||||||||
| White | 1995–2011 | 100 | 101 | 0.0 (−0.1 to 0.1) | reference | 1995–2008 | 96 | 82 | −1.5 (−2.1 to −0.9) | reference | 0.494 |
| 2008–2011 | 82 | 97 | 6.4 (2.7 to 10.1) | ||||||||
| Black* | 1998–2010 | 97 | 90 | 0.7 (0.1 to 1.4) | 0.082 | 51 | 99 | 2.0 (1.2 to 2.8) | 0.015 | 0.004 | |
| Other | 1995–2011 | 93 | 98 | 0.4 (0.2 to 0.7) | 0.001 | 1995–2008 | 72 | 74 | 0.3 (−0.4 to 1.0) | <0.001 | 0.004 |
| 2008–2011 | 74 | 93 | 5.9 (3.6 to 8.3) | ||||||||
| Histology | |||||||||||
| IDC | 1995–2011 | 96 | 101 | 0.3 (0.2 to 0.5) | reference | 1995–2008 | 80 | 83 | 0.2 (−0.1 to 0.4) | reference | <0.001 |
| 2008–2011 | 83 | 96 | 5.3 (3.8 to 6.9) | ||||||||
| ILC | 1995–2011 | 85 | 101 | 0.3 (0.1 to 0.5) | 0.626 | 1995–2007 | 87 | 82 | −0.6 (−1.5 to 0.3) | 0.203 | <0.001 |
| 2007–2011 | 82 | 98 | 4.7 (2.5 to 7.0) | ||||||||
| MDLC | 1995–2011 | 97 | 101 | 0.3 (0.1 to 0.5) | 0.89 | 1995–2008 | 86 | 76 | 0.0 (−0.9 to 0.9) | 0.858 | 0.012 |
| 2008–2011 | 76 | 99 | 5.1 (2.0 to 8.3) | ||||||||
| Other | 1995–2006 | 86 | 106 | 1.5 (0.8 to 2.1) | 0.009 | 1995–2006 | 65 | 63 | 0.2 (−0.6 to 0.9) | 0.003 | 0.009 |
| 2006–2011 | 100 | 97 | −2.5 (−5.0 to 0.0) | 2006–2011 | 63 | 86 | 5.2 (3.8 to 6.7) | ||||
| Staging | |||||||||||
| Stage 1 | 1995–2009 | 96 | 104 | 0.2 (−0.1 to 0.6) | reference | 1995–2011 | 96 | 100 | 0.3 (0.1 to 0.5) | reference | 0.002 |
| 2009–2011 | 104 | 100 | −2.0 (−4.7 to 0.8) | ||||||||
| Stage 2 | 1995–2011 | 62 | 101 | 0.6 (0.4 to 0.9) | 0.014 | 1995–2006 | 80 | 83 | 0.8 (0.3 to 1.4) | 0.006 | 0.053 |
| 2006–2011 | 83 | 99 | 2.9 (2.0 to 3.7) | ||||||||
| Stage 3 | 1995–1998 | 7 | 89 | 347.0 (−67.1 to 5,981.0) | <0.001 | 1995–2011 | 41 | 98 | 5.6 (4.4 to 6.8) | <0.001 | <0.001 |
| 1998–2011 | 89 | 101 | 1.4 (0.5 to 2.4) | ||||||||
| Stage 4 | 1995–2011 | 26 | 94 | 5.2 (2.2 to 8.2) | <0.001 | 1995–2007 | 16 | 17 | −4.1 (−15.5 to 8.8) | <0.001 | 0.009 |
| 2007–2011 | 17 | 68 | 40.5 (11.2 to 77.6) | ||||||||
| Grade | |||||||||||
| Grade 1 | 1995–2006 | 99 | 106 | 0.3 (0.0 to 0.6) | reference | 1995–2011 | 98 | 97 | 0.1 (−0.1 to 0.3) | reference | <0.001 |
| 2006–2011 | 106 | 101 | −0.8 (−1.3 to −0.4) | ||||||||
| Grade 2 | 1995–2011 | 98 | 101 | 0.3 (0.2 to 0.5) | 0.005 | 1995–2008 | 88 | 87 | 0.1 (−0.2 to 0.4) | 0.004 | <0.001 |
| 2008–2011 | 87 | 98 | 3.7 (2.4 to 5.0) | ||||||||
| Grade 3 | 1995–2011 | 87 | 99 | 0.8 (0.5 to 1.2) | <0.001 | 1995–2008 | 65 | 75 | 1.1 (0.8 to 1.5) | <0.001 | <0.001 |
| 2008–2011 | 75 | 94 | 8.0 (6.3 to 9.8) | ||||||||
APC, annual percentage change; CI, confidence intervals; NS, age-standardized five-year net survival; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MDLC, mixed ductal and lobular carcinoma; NA, not available; p, p-values of parallelism test for the within group differences (< 0.05 indicates different slopes/trends compared with the reference);
*
data missing in some years.